Iovance Biotherapeutics, Inc. IOVA Notes Payable
Notes Payable at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NotesPayableCurrent.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s notes payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s notes payable?
- Iovance Biotherapeutics, Inc. (IOVA) reported notes payable of $1M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s notes payable changed year-over-year?
- Iovance Biotherapeutics, Inc.'s notes payable decreased by 0.0% year-over-year, from $1M to $1M.
- What does notes payable mean?
- Notes payable represents formal written promises to pay a specific sum of money at a future date, often including interest obligations. For a clinical-stage biopharmaceutical company, this metric reflects the firm's reliance on debt financing to fund research, development, and commercialization activities. Monitoring this balance helps investors assess the company's leverage, liquidity risk, and the cost of capital required to sustain operations prior to achieving consistent product revenue.